ZENOTECHPharmaceuticals
Zenotech Laboratories Ltd — Cash Flow Statement
₹34.29
-5.60%
Zenotech Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 5.63 Cr | 7.59 Cr | 14.43 Cr | 15.73 Cr | — |
| Repayment Of Debt | 0.00 | 0.00 | -6.00 Cr | -14.66 Cr | — |
| Capital Expenditure | -3.86 Cr | -4.23 Cr | -6.23 Cr | -1.94 Cr | — |
| End Cash Position | 26.58 Cr | 1.82 Cr | 11.14 Cr | 2.41 Cr | — |
| Beginning Cash Position | 1.82 Cr | 11.14 Cr | 2.41 Cr | 2.46 Cr | — |
| Effect Of Exchange Rate Changes | -0.02 Cr | 54000.00 | 0.00 | — | — |
| Changes In Cash | 24.78 Cr | -9.33 Cr | 8.73 Cr | -0.04 Cr | — |
| Financing Cash Flow | 0.00 | 0.00 | -6.11 Cr | -15.87 Cr | — |
| Interest Paid Cff | 0.00 | 0.00 | -0.11 Cr | -1.22 Cr | — |
| Net Issuance Payments Of Debt | 0.00 | 0.00 | -6.00 Cr | -14.66 Cr | — |
| Net Long Term Debt Issuance | 0.00 | 0.00 | -6.00 Cr | -14.66 Cr | — |
| Long Term Debt Payments | 0.00 | 0.00 | -6.00 Cr | -14.66 Cr | — |
| Investing Cash Flow | 15.29 Cr | -21.15 Cr | -5.82 Cr | -1.84 Cr | — |
| Interest Received Cfi | 1.41 Cr | 0.95 Cr | 0.37 Cr | 0.10 Cr | — |
| Net Investment Purchase And Sale | 17.74 Cr | -17.87 Cr | 0.00 | — | — |
| Net PPE Purchase And Sale | -3.86 Cr | -4.23 Cr | -6.19 Cr | -1.94 Cr | — |
| Sale Of PPE | 0.00 | 37000.00 | 0.04 Cr | 0.00 | — |
| Purchase Of PPE | -3.86 Cr | -4.23 Cr | -6.23 Cr | -1.94 Cr | — |
| Operating Cash Flow | 9.49 Cr | 11.82 Cr | 20.66 Cr | 17.67 Cr | — |
| Taxes Refund Paid | -1.94 Cr | -1.07 Cr | -1.19 Cr | -1.00 Cr | — |
| Change In Working Capital | -2.89 Cr | -4.41 Cr | 0.49 Cr | 0.76 Cr | — |
| Change In Other Current Liabilities | 0.53 Cr | -1.00 Cr | -0.37 Cr | 0.63 Cr | — |
| Change In Other Current Assets | 0.54 Cr | -0.68 Cr | -1.40 Cr | 0.05 Cr | — |
| Change In Payable | -0.75 Cr | -0.17 Cr | 1.43 Cr | 0.22 Cr | — |
| Change In Inventory | 0.84 Cr | -0.84 Cr | 0.06 Cr | 11000.00 | — |
| Change In Receivables | -4.20 Cr | 0.07 Cr | 0.60 Cr | -0.13 Cr | — |
| Other Non Cash Items | -1.41 Cr | -0.95 Cr | -0.26 Cr | 1.12 Cr | — |
| Depreciation And Amortization | 6.96 Cr | 7.09 Cr | 7.17 Cr | 6.97 Cr | — |
| Depreciation | 6.96 Cr | 7.09 Cr | 7.17 Cr | 6.97 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.02 Cr | -54000.00 | 6000.00 | 27000.00 | — |
| Gain Loss On Sale Of PPE | 0.00 | 0.04 Cr | -0.04 Cr | 0.00 | — |
| Net Income From Continuing Operations | 10.69 Cr | 11.14 Cr | 14.50 Cr | 9.90 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 1000.00 | — | — | — |
| Issuance Of Debt | — | — | — | 0.00 | 2.00 Cr |
| Issuance Of Capital Stock | — | — | — | 0.00 | 0.00 |
| Net Common Stock Issuance | — | — | — | 0.00 | 0.00 |
| Common Stock Issuance | — | — | — | 0.00 | 0.00 |
| Long Term Debt Issuance | — | — | — | 0.00 | 2.00 Cr |
| Net Other Investing Changes | — | — | — | — | 0.04 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zenotech Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.